Mineralys CEO John Congleton describes the rational of targeting aldosterone for hypertension and discusses his company's pivotal data
He describes the science behind aldosterone and Mineralys' program lorundrostat. The company had pivotal data earlier this year and plans to have a pre-NDA meeting with FDA in the fourth quarter.
Coverage brought to you by:











.png)